

- **Name:** Ken Kato
 - **Current Position & Affiliation:** Chief, Department of Head and Neck, Esophageal Medical Oncology
 - **Country:** Japan
-

- **Educational Background:**

N/A

- **Professional Experience:**

- 2004-2006 Chief Resident, National Cancer Center Hospital, Tokyo
- 2006-2012 Medical staff, Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo
- 2013-Present Chief, Biobank Translational Research Support Section, Clinical Research Coordinating Section, Clinical Research Support Office
- 2020-Present Chief, Department of Head and Neck, Esophageal Medical Oncology, National Cancer Center Hospital, Tokyo
- 2021-Present Chief, Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo

- **Professional Organizations:**

N/A

- **Main Scientific Publications:**

- 2019 Kato K, et al. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019 Sep 27.: S1470-2045(19)30626-6.
- 2021 Sun JM, Kato K, et al. Pembrolizumab plus chemotherapy versus chemotherapy for first-line, advanced esophageal cancer: the randomized, placebo-controlled phase 3 KEYNOTE-590 study Lancet in press 2021
- 2021 Kato K, et al. Parallel-group controlled trial of surgery versus chemoradiotherapy in patients with stage I esophageal squamous cell carcinoma. Gastroenterology 2021, Aug 10; S0016-5085(21)03352-7